Skip to main content
FDA prioritizes review of Galt's opioid-free analgesic
5/31/2019

The FDA has granted priority review designation to Galt Pharmaceuticals' supplemental abbreviated new drug application for Orphengesic Forte, a combination nonopioid analgesic. The agency has set a PDUFA date of Aug. 14.

Full Story: